TRIM17 and osteosarcoma: In view of the carcinogenic effect of TRIM17 in tumors, the key position of the AKT/mTOR pathway in osteosarcoma, and the potential function of FTO as a regulatory factor of m6A modification, we propose the hypothesis: TRIM17 can activate the AKT/mTOR pathway and promote the progression of osteosarcoma by regulating FTO-mediated PDK1 m6A modification.